Synthetic Biologics, Inc

(NYSE MKT:SYN)

Latest On Synthetic Biologics, Inc (SYN):

Date/Time Type Description Signal Details
2022-09-27 17:24 ESTNewsSafety board recommends Synthetic Biologics proceed in cell transplant recipients trialN/A
2022-09-06 15:24 ESTNewsSynthetic Biologics VCN-01 shows safety in phase 1 trial in head/neck cancerN/A
2022-08-11 16:05 ESTNewsSynthetic Biologics GAAP EPS of -$0.31N/A
2022-08-11 16:04 ESTNewsSynthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 23:57 ESTNewsSynthetic Biologics Q2 2022 Earnings PreviewN/A
2022-07-15 20:16 ESTNewsSynthetic Biologics stock slides on reverse stock split announcementN/A
2022-05-16 19:40 ESTNewsSynthetic Biologics GAAP EPS of -$0.03 in-lineN/A
2022-05-16 19:39 ESTNewsSynthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-10 14:29 ESTNewsSynthetic Biologics stock rises as oral drug SYN-020 shows safety in early-stage studyN/A
2022-03-17 23:24 ESTNewsSynthetic Biologics GAAP EPS of -$0.19 misses by $0.01N/A
2022-03-17 23:24 ESTNewsSynthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-16 12:27 ESTNewsSynthetic Biologics FY 2021 Earnings PreviewN/A
2022-02-09 01:08 ESTNewsSynthetic Biologics says VCN's therapy for retinoblastoma gets FDA's orphan drug statusN/A
2021-12-14 22:23 ESTNewsSynthetic Biologics to acquire VCN Biosciences for over $4M in upfront cashN/A
2021-11-03 19:30 ESTNewsSynthetic Biologics EPS beats by $0.01N/A
2021-11-03 19:29 ESTNewsSynthetic Biologics, Inc.'s (SYN) CEO Steven Shallcross on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-21 17:39 ESTNewsSynthetic Biologics initiates early-stage trial for SYN-020 intestinal alkaline phosphataseN/A
2021-08-06 11:13 ESTNewsSynthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2021 Results - Earnings Call TranscriptN/A
2021-05-05 23:52 ESTNewsSynthetic Biologics reports Q1 resultsN/A
2021-05-05 23:51 ESTNewsSynthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2021 Results - Earnings Call TranscriptN/A
2021-05-04 06:21 ESTNewsSynthetic Biologics files for $300M mixed shelf offeringN/A
2021-04-01 23:40 ESTNewsDosing underway in Synthetic Bio's early-stage SYN-020 study in intestinal alkaline phosphataseN/A
2021-03-23 10:37 ESTNewsSizing Up Synthetic BiologicsN/A
2021-03-16 22:09 ESTAnalyst RatingThe Analyst Target Price has increased from $1.25 to $1.88.Buy
2021-03-09 08:41 ESTEarnings EstimateAn EPS average of -$0.03 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-06 08:39 ESTFinancialsCompany financials have been released.Neutral
2021-03-05 08:42 ESTEarnings EstimateAn EPS average of -$0.19 is estimated for the 2022 year.Sell
2021-03-05 05:48 ESTNewsSynthetic Biologics EPS misses by $0.10N/A
2021-03-05 05:48 ESTNewsSynthetic Biologics, Inc's (SYN) CEO Steve Shallcross on Q4 2020 Results - Earnings Call TranscriptN/A
2020-12-23 02:33 ESTNewsSynthetic Biologics on go with early-stage study with SYN-004N/A
2020-11-26 21:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 05:30 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 05:49 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 13:06 ESTEarnings EstimateAn EPS average of -$0.15 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-11 01:23 ESTNewsSynthetic Biologics EPS beats by $0.03N/A
2020-11-11 01:23 ESTNewsSynthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-08 01:01 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:16 ESTFinancialsCompany financials have been released.Neutral
2020-10-05 06:12 ESTAnalyst RatingThe Analyst Target Price has decreased from $1.38 to $1.25.Neutral
2020-10-03 08:42 ESTNewsSynthetic Bio's lead candidate flunks irritable bowel study; shares down 42%N/A
2020-09-26 14:10 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:22 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 10:15 ESTFinancialsCompany financials have been released.Neutral
2020-08-09 05:47 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 02:56 ESTNewsSynthetic Biologics EPS in-lineN/A
2020-08-07 02:55 ESTNewsSynthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-06 09:38 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 06:04 ESTNewsSynthetic Biologics on go with first study of enzyme therapy for gut healthN/A
2020-07-30 17:59 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:57 ESTFinancialsCompany financials have been released.Neutral

About Synthetic Biologics, Inc (SYN):

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.

SYN Quotes by TradingView

See Advanced Chart

General

  • Name Synthetic Biologics, Inc
  • Symbol SYN
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Last Split Factor1:35
  • Last Split Date2018-08-13
  • Fiscal Year EndDecember
  • IPO Date2006-06-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.syntheticbiologics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 77.81
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.09
  • Next Year EPS Estimate -$0.12
  • Return on Assets -50%
  • Return on Equity -121%
  • Earnings Per Share -$2.12
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 102.44 million
  • EBITDA -14536000
  • Analyst Target Price $1.88
  • Book Value Per Share $0.01
View More

Share Statistics

  • Shares Outstanding 129.66 million
  • Shares Float 127.36 million
  • % Held by Insiders 37%
  • % Held by Institutions 7.12%
  • Shares Short 9.74 million
  • Shares Short Prior Month 1.97 million
  • Short Ratio 0.54
  • Short % of Float 9%
  • Short % of Shares Outstanding 9%
View More

Technicals

  • Beta 2.02
  • 52 Week High $1.22
  • 52 Week Low $0.28
  • 50 Day Moving Average 0.81
  • 200 Day Moving Average 0.55
View More

Dividends

  • Dividend Date 2018-08-13
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Synthetic Biologics, Inc (SYN) Dividend Calendar:

SYN's last dividend payment was made to shareholders on August 13, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Synthetic Biologics, Inc (SYN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$N/A-$0.14-$0.08-75%
2020-09-302020-11-10$N/A-$0.14-$0.1717.65%
2020-06-302020-08-06$N/A-$0.18-$0.180%
2020-03-312020-05-05$N/A-$0.20-$0.2725.93%
2019-12-312020-02-20$N/A-$0.19-$0.2317.39%
2019-09-302019-11-04$N/A-$0.31-$0.23-34.78%
2019-06-302019-08-08$N/A-$0.22-$0.234.35%
2019-03-312019-05-08$N/A-$0.22-$0.234.35%
2018-12-312019-02-27$N/A-$1.33-$0.20-582.05%
2018-09-302018-11-08$N/A-$0.93-$1.3329.81%
2018-06-302018-08-08$N/A-$1.05-$1.4025%
2018-03-312018-05-08$N/A-$0.70-$1.7560%
2017-12-312018-02-22$N/A$0.70-$1.63142.86%
2017-09-302017-11-01$N/A-$4.90-$1.52-223.07%
2017-06-302017-08-03$N/A-$1.05-$1.9847.06%
2017-03-312017-05-04$N/A-$0.70-$2.5772.73%
2016-12-312017-03-02$N/A-$0.70-$2.7374.36%
2016-09-302016-11-01$N/A-$3.15-$3.6814.29%
2016-06-302016-08-03$N/A-$2.10-$3.9747.06%
2016-03-312016-05-05$N/A-$4.20-$4.649.43%
2015-12-312016-03-10$N/A-$4.20-$4.343.23%
2015-09-302015-11-05$N/A-$0.08-$0.1233.33%
2015-06-302015-08-10$N/A-$0.19-$0.11-72.73%
2015-03-312015-05-11$N/A-$0.17-$0.08-112.5%
2014-12-312015-03-16$N/A-$0.09-$0.06-50%
2014-09-302014-11-14$N/A-$0.08-$0.05-60%
2014-06-302014-08-14$N/A-$2.80-$2.27-23.35%
2014-03-312014-05-15$N/A-$2.45-$2.688.58%
2013-12-312014-03-31$N/A-$3.15-$2.22-41.89%
2013-09-302013-11-14$N/A-$2.80-$2.01-39.3%
2013-06-302013-08-14$N/A-$2.10-$1.92-9.38%
2013-03-312013-04-16$N/A-$11.90-$1.23-867.48%
2012-09-302012-11-20$N/A-$2.02
2012-06-302012-08-13$N/A-$1.98
2012-03-312012-05-15$N/A-$1.31
2011-12-312012-03-30$N/A-$3.85-$1.05-266.67%
2011-09-302011-11-14$293421-$1.05-$1.4025%
2011-06-302011-08-15$355562-$2.11
2011-03-312011-05-16$N/A-$3.03
2010-09-302010-11-15$290000-$1.12
2010-06-302010-08-16$2.2 million$1.57
2010-03-312010-05-18$60000-$1.77
2009-12-312010-03-03$52000-$1.83
2009-09-302009-11-17$51000-$1.02
2009-06-302009-08-14$N/A-$1.45
2009-03-312009-05-15$N/A-$1.87
2008-12-312009-03-31$N/A-$1.40-$2.4542.86%
2008-09-302008-11-14$N/A-$2.41
2008-06-302008-08-14$N/A-$3.15-$3.8518.18%
2008-03-312008-05-15$N/A-$5.25-$4.90-7.14%
2007-12-312008-03-31$N/A-$8.05-$4.20-91.67%
2007-09-302007-11-14$N/A-$4.20-$4.200%
2007-06-302007-08-13$N/A-$3.50-$4.2016.67%
2007-03-312007-05-15$N/A-$31.45
2006-12-312007-03-08$N/A-$31.50
2006-09-302006-11-17$N/A-$0.10
2006-06-302006-08-16$N/A-$0.19
2006-03-312006-05-16$N/A$0.00
2005-12-312006-03-09$N/A-$1.08
2005-09-302005-11-18$N/A-$1.14
2005-06-302005-08-17$N/A$0.00
2005-03-312005-05-10$N/A$0.00
2004-12-312005-03-10$0.00
2004-09-302004-11-12$0.00
2004-06-302004-08-11$0.00
2004-03-312004-05-11$0.00
2003-09-302003-11-14$0.00
2003-06-302003-08-13$14,420.73
2003-03-312003-05-13-$1,324.51
2002-09-302002-11-15-$1,691.31
2002-06-302002-08-14-$3,345.76
2002-03-312002-05-01-$3,333.51
2001-09-302001-11-01-$9.45-$5.25-80%
2001-06-302001-08-02-$8.40-$5.25-60%
2001-03-312001-03-31-$1,438.90
2000-09-302000-09-30-$1,231.18
2000-06-302000-06-30-$1,298.31
2000-03-312000-03-31-$1,386.23
1999-09-301999-11-09-$5.25-$3.15-66.67%
1999-06-301999-06-30-$1,430.88
1999-03-311999-03-31-$1,127.12
1998-09-301998-09-30-$2,093.62
1998-06-301998-06-30-$17,501.61
1998-03-311998-03-31-$4,395.58
1996-12-311997-03-27-$19.95-$16.80-18.75%

Synthetic Biologics, Inc (SYN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Synthetic Biologics, Inc (SYN) Chart:

SYN chart by TradingView

Synthetic Biologics, Inc (SYN) News:

Below you will find a list of latest news for Synthetic Biologics, Inc (SYN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Synthetic Biologics, Inc (SYN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest SYN Trades:

Date Shares Price
Jun 13, 2022 4:19 PM EST22$0.1982
Jun 13, 2022 4:35 PM EST100$0.2004
Jun 13, 2022 4:35 PM EST100$0.2004
Jun 13, 2022 4:35 PM EST100$0.2004
Jun 13, 2022 7:23 PM EST200$0.2021

Synthetic Biologics, Inc (SYN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000110465920056927/0001104659-20-056927-index.htm
2018-05-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/894158/000000000018014999/0000000000-18-014999-index.htm
2018-08-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/894158/000000000018025271/0000000000-18-025271-index.htm
2018-09-25UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/894158/000000000018030213/0000000000-18-030213-index.htm
2018-10-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/894158/000093041318003095/0000930413-18-003095-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/894158/000093041319000505/0000930413-19-000505-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/894158/000093041320000372/0000930413-20-000372-index.htm
2019-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465919059502/0001104659-19-059502-index.htm
2019-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000110465919059538/0001104659-19-059538-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465919068217/0001104659-19-068217-index.htm
2019-12-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465919070212/0001104659-19-070212-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000110465919070227/0001104659-19-070227-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000110465919070228/0001104659-19-070228-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000110465919070375/0001104659-19-070375-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000110465919070376/0001104659-19-070376-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465920001775/0001104659-20-001775-index.htm
2020-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465920012556/0001104659-20-012556-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465920023392/0001104659-20-023392-index.htm
2020-02-2010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/894158/000110465920023415/0001104659-20-023415-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465920056877/0001104659-20-056877-index.htm
2020-05-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000110465920056927/0001104659-20-056927-index.htm
2020-08-04DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/894158/000110465920090343/0001104659-20-090343-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465920090908/0001104659-20-090908-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465920091457/0001104659-20-091457-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000110465920091503/0001104659-20-091503-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465920106311/0001104659-20-106311-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000110465920111398/0001104659-20-111398-index.htm
2020-10-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/894158/000110465920119032/0001104659-20-119032-index.htm
2019-04-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/894158/000114036119006440/0001140361-19-006440-index.htm
2017-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420417064825/0001144204-17-064825-index.htm
2017-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420417064828/0001144204-17-064828-index.htm
2017-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420417064829/0001144204-17-064829-index.htm
2017-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420417064830/0001144204-17-064830-index.htm
2018-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418001184/0001144204-18-001184-index.htm
2018-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418010096/0001144204-18-010096-index.htm
2018-02-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/894158/000114420418010286/0001144204-18-010286-index.htm
2018-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418013351/0001144204-18-013351-index.htm
2018-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418021693/0001144204-18-021693-index.htm
2018-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418025766/0001144204-18-025766-index.htm
2018-05-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/894158/000114420418025776/0001144204-18-025776-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418026138/0001144204-18-026138-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000114420418026171/0001144204-18-026171-index.htm
2018-05-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/894158/000114420418028259/0001144204-18-028259-index.htm
2018-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418030165/0001144204-18-030165-index.htm
2018-08-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/894158/000114420418041398/0001144204-18-041398-index.htm
2018-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418041405/0001144204-18-041405-index.htm
2018-08-01PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/894158/000114420418041412/0001144204-18-041412-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418042817/0001144204-18-042817-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000114420418042887/0001144204-18-042887-index.htm
2018-08-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/894158/000114420418042966/0001144204-18-042966-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418043710/0001144204-18-043710-index.htm
2018-08-14DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/894158/000114420418044161/0001144204-18-044161-index.htm
2018-08-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/894158/000114420418045084/0001144204-18-045084-index.htm
2018-08-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/894158/000114420418045633/0001144204-18-045633-index.htm
2018-09-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418048214/0001144204-18-048214-index.htm
2018-09-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418048215/0001144204-18-048215-index.htm
2018-09-18S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/894158/000114420418049861/0001144204-18-049861-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418050928/0001144204-18-050928-index.htm
2018-10-02S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/894158/000114420418052016/0001144204-18-052016-index.htm
2018-10-02FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/894158/000114420418052018/0001144204-18-052018-index.htm
2018-10-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/894158/000114420418052101/0001144204-18-052101-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418052119/0001144204-18-052119-index.htm
2018-10-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/894158/000114420418052521/0001144204-18-052521-index.htm
2018-10-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/894158/000114420418052523/0001144204-18-052523-index.htm
2018-10-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418053098/0001144204-18-053098-index.htm
2018-10-10S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/894158/000114420418053149/0001144204-18-053149-index.htm
2018-10-10S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/894158/000114420418053211/0001144204-18-053211-index.htm
2018-10-12424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/894158/000114420418053648/0001144204-18-053648-index.htm
2018-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418053807/0001144204-18-053807-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418058370/0001144204-18-058370-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000114420418058414/0001144204-18-058414-index.htm
2018-11-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418061119/0001144204-18-061119-index.htm
2018-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418062336/0001144204-18-062336-index.htm
2018-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420418063398/0001144204-18-063398-index.htm
2018-12-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420418063625/0001144204-18-063625-index.htm
2018-12-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420418063627/0001144204-18-063627-index.htm
2018-12-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420418063628/0001144204-18-063628-index.htm
2018-12-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420418063630/0001144204-18-063630-index.htm
2019-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420419000236/0001144204-19-000236-index.htm
2019-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420419010544/0001144204-19-010544-index.htm
2019-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/894158/000114420419010592/0001144204-19-010592-index.htm
2019-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420419012008/0001144204-19-012008-index.htm
2019-04-0110-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/894158/000114420419017481/0001144204-19-017481-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420419024512/0001144204-19-024512-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000114420419024539/0001144204-19-024539-index.htm
2019-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420419033241/0001144204-19-033241-index.htm
2019-07-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/894158/000114420419034736/0001144204-19-034736-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420419038566/0001144204-19-038566-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420419038572/0001144204-19-038572-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/894158/000114420419038590/0001144204-19-038590-index.htm
2019-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000114420419041677/0001144204-19-041677-index.htm
2019-09-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/894158/000114420419043618/0001144204-19-043618-index.htm
2019-09-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/894158/000114420419046080/0001144204-19-046080-index.htm
2019-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/894158/000139382519000099/0001393825-19-000099-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/894158/000145307218000061/0001453072-18-000061-index.htm
2019-01-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/894158/000153561019000054/0001535610-19-000054-index.htm
2019-01-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/894158/000153561019000055/0001535610-19-000055-index.htm
2020-01-21SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/894158/000153561020000046/0001535610-20-000046-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm
2018-05-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/894158/999999999518001264/9999999995-18-001264-index.htm
2018-08-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/894158/999999999518002172/9999999995-18-002172-index.htm
2018-10-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/894158/999999999518002587/9999999995-18-002587-index.htm

Synthetic Biologics, Inc (SYN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Synthetic Biologics, Inc (SYN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 37%
Institutional Ownership: 712%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-04-03RANDAL J KIRK10% Share HolderSell69,161.000.6544,954.65165,332.00https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm
2019-04-02RANDAL J KIRK10% Share HolderSell9,909.000.666,539.94234,493.00https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm
2019-04-01RANDAL J KIRK10% Share HolderSell30,265.000.6720,277.55244,402.00https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm
2019-08-23SHALLCROSS STEVEN ACEO and CFOBuy50,000.000.4220,785.0050,000.00https://www.sec.gov/Archives/edgar/data/894158/000114420419041677/0001144204-19-041677-index.htm
2019-04-03RANDAL J KIRK10% Share HolderSell26,080.000.6516,952.0062,342.00https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm
2019-04-02RANDAL J KIRK10% Share HolderSell3,737.000.662,466.4288,422.00https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm
2019-04-01RANDAL J KIRK10% Share HolderSell11,413.000.677,646.7192,159.00https://www.sec.gov/Archives/edgar/data/894158/000156761919008334/0001567619-19-008334-index.htm